CN102458445A - Fviii衍生肽 - Google Patents
Fviii衍生肽 Download PDFInfo
- Publication number
- CN102458445A CN102458445A CN2010800323370A CN201080032337A CN102458445A CN 102458445 A CN102458445 A CN 102458445A CN 2010800323370 A CN2010800323370 A CN 2010800323370A CN 201080032337 A CN201080032337 A CN 201080032337A CN 102458445 A CN102458445 A CN 102458445A
- Authority
- CN
- China
- Prior art keywords
- peptide
- factor
- fviii
- sequence
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 231
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims abstract description 89
- 102100026735 Coagulation factor VIII Human genes 0.000 claims abstract description 86
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 49
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 36
- 201000003542 Factor VIII deficiency Diseases 0.000 claims abstract description 22
- 230000030741 antigen processing and presentation Effects 0.000 claims abstract description 22
- 208000013633 acquired hemophilia Diseases 0.000 claims abstract description 15
- 108010076282 Factor IX Proteins 0.000 claims description 66
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 65
- 229960004222 factor ix Drugs 0.000 claims description 65
- 235000001014 amino acid Nutrition 0.000 claims description 56
- 150000001413 amino acids Chemical class 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 23
- 108010051539 HLA-DR2 Antigen Proteins 0.000 claims description 21
- 238000012986 modification Methods 0.000 claims description 11
- 230000004048 modification Effects 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 10
- 238000009256 replacement therapy Methods 0.000 claims description 10
- 229940117942 Factor IX inhibitor Drugs 0.000 claims description 9
- 230000005611 electricity Effects 0.000 claims description 9
- 230000002209 hydrophobic effect Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 240000002853 Nelumbo nucifera Species 0.000 claims description 5
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 5
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 abstract description 27
- 108010054218 Factor VIII Proteins 0.000 abstract description 3
- 102000001690 Factor VIII Human genes 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract description 2
- 229960000301 factor viii Drugs 0.000 abstract description 2
- 230000001629 suppression Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 32
- 230000004044 response Effects 0.000 description 29
- 210000000612 antigen-presenting cell Anatomy 0.000 description 17
- 208000031220 Hemophilia Diseases 0.000 description 16
- 208000009292 Hemophilia A Diseases 0.000 description 16
- 208000032843 Hemorrhage Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 108090000190 Thrombin Proteins 0.000 description 12
- 230000023555 blood coagulation Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 229960004072 thrombin Drugs 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 230000002950 deficient Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 8
- 210000001165 lymph node Anatomy 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000008034 disappearance Effects 0.000 description 7
- 208000009429 hemophilia B Diseases 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229960004641 rituximab Drugs 0.000 description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 229940099816 human factor vii Drugs 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 231100000749 chronicity Toxicity 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 206010060820 Joint injury Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 210000000088 lip Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229940124135 Factor VIII inhibitor Drugs 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000005168 Intussusception Diseases 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- 206010037437 Pulmonary thrombosis Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000000145 adjuvantlike effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- -1 aromatic amino acid Chemical class 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940105776 factor viii inhibitor bypassing activity Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960000027 human factor ix Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940047434 kogenate Drugs 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108010012557 prothrombin complex concentrates Proteins 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 230000007575 pulmonary infarction Effects 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001745 uvea Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
GTLMVFFGNVDSSGI |
TQTLHKFILLFAVFD |
SLYISQFIIMYSLDG |
PPIIARYIRLHPTHY |
PPLLTRYLRIHPQSW |
MHTVNGYVNRSLPGL |
LGQFLLFCHISSHQH |
DTLLIIFKNQASRPY |
PRCLTRYYSSFVNME |
TENIQRFLPNPAGVQ |
DNIMVTFRNQASRPY |
RYLRIHPQSWVHQIA |
GTLMVFFGNVDSSGI |
TQTLHKFILLFAVFD |
SLYISQFIIMYSLDG |
PPIIARYIRLHPTHY |
PPLLTRYLRIHPQSW |
MHTVNGYVNRSLPGL |
LGQFLLFCHISSHQH |
DTLLIIFKNQASRPY |
PRCLTRYYSSFVNME |
TENIQRFLPNPAGVQ |
DNIMVTFRNQASRPY |
RYLRIHPQSWVHQIA |
GTLMVFFGNVDSSGI |
TQTLHKFILLFAVFD |
SLYISQFIIMYSLDG |
PPIIARYIRLHPTHY |
PPLLTRYLRIHPQSW |
MHTVNGYVNRSLPGL |
LGQFLLFCHISSHQH |
DTLLIIFKNQASRPY |
PRCLTRYYSSFVNME |
TENIQRFLPNPAGVQ |
DNIMVTFRNQASRPY |
RYLRIHPQSWVHQIA |
Claims (18)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0908515.0A GB0908515D0 (en) | 2009-05-18 | 2009-05-18 | Peptide |
GB0908515.0 | 2009-05-18 | ||
PCT/GB2010/000997 WO2010133834A2 (en) | 2009-05-18 | 2010-05-17 | Peptide |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102458445A true CN102458445A (zh) | 2012-05-16 |
CN102458445B CN102458445B (zh) | 2014-06-11 |
Family
ID=40834163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080032337.0A Expired - Fee Related CN102458445B (zh) | 2009-05-18 | 2010-05-17 | Fviii衍生肽 |
Country Status (31)
Country | Link |
---|---|
US (1) | US8703705B2 (zh) |
EP (2) | EP2465523B1 (zh) |
JP (1) | JP5784009B2 (zh) |
KR (1) | KR101673889B1 (zh) |
CN (1) | CN102458445B (zh) |
AU (1) | AU2010250957B2 (zh) |
BR (1) | BRPI1012845A2 (zh) |
CA (1) | CA2762020C (zh) |
CL (1) | CL2011002893A1 (zh) |
CO (1) | CO6460780A2 (zh) |
CY (1) | CY1115832T1 (zh) |
DK (1) | DK2465523T3 (zh) |
EA (1) | EA027229B1 (zh) |
EC (1) | ECSP11011540A (zh) |
ES (1) | ES2525448T3 (zh) |
GB (1) | GB0908515D0 (zh) |
HK (1) | HK1173358A1 (zh) |
HR (1) | HRP20141182T1 (zh) |
IL (1) | IL216199A (zh) |
MX (1) | MX2011012270A (zh) |
MY (1) | MY168207A (zh) |
NZ (2) | NZ613713A (zh) |
PL (1) | PL2465523T3 (zh) |
PT (1) | PT2465523E (zh) |
RS (1) | RS53671B1 (zh) |
SG (2) | SG190573A1 (zh) |
SI (1) | SI2465523T1 (zh) |
SM (1) | SMT201400186B (zh) |
UA (1) | UA110921C2 (zh) |
WO (1) | WO2010133834A2 (zh) |
ZA (1) | ZA201108446B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104903347A (zh) * | 2012-11-12 | 2015-09-09 | 艾匹托普国际股份有限公司 | 肽 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2506868T (lt) | 2009-12-06 | 2018-02-26 | Bioverativ Therapeutics Inc. | Faktoriaus viii-fc chimeriniai ir hibridiniai polipeptidai ir jų panaudojimo būdai |
GB201314052D0 (en) * | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
PE20231949A1 (es) | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060917A2 (en) * | 2000-12-01 | 2002-08-08 | Regents Of The University Of Minnesota | Method to treat hemophilia |
WO2002098454A2 (en) * | 2001-05-31 | 2002-12-12 | D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
WO2009095646A2 (en) * | 2008-01-28 | 2009-08-06 | Circassia Limited | Peptides from factor viii |
CN101889024A (zh) * | 2007-12-04 | 2010-11-17 | 艾匹托普技术(布里斯托尔)有限公司 | Fviii肽和它们用于耐受化血友病患者的用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1311542B1 (en) | 2000-08-21 | 2008-07-16 | Apitope Technology (Bristol) Limited | Tolerogenic peptides |
WO2002096454A1 (en) | 2001-05-31 | 2002-12-05 | D. Collen Research Foundation Vzw | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
CN1646564A (zh) | 2002-04-18 | 2005-07-27 | 默克专利有限公司 | 修饰的因子ⅷ |
-
2009
- 2009-05-18 GB GBGB0908515.0A patent/GB0908515D0/en not_active Ceased
-
2010
- 2010-05-17 EA EA201171430A patent/EA027229B1/ru not_active IP Right Cessation
- 2010-05-17 SG SG2013030713A patent/SG190573A1/en unknown
- 2010-05-17 KR KR1020117028276A patent/KR101673889B1/ko active IP Right Grant
- 2010-05-17 NZ NZ613713A patent/NZ613713A/en not_active IP Right Cessation
- 2010-05-17 SI SI201030819T patent/SI2465523T1/sl unknown
- 2010-05-17 DK DK12159740.5T patent/DK2465523T3/en active
- 2010-05-17 SG SG2011084985A patent/SG176138A1/en unknown
- 2010-05-17 AU AU2010250957A patent/AU2010250957B2/en not_active Ceased
- 2010-05-17 PL PL12159740T patent/PL2465523T3/pl unknown
- 2010-05-17 MX MX2011012270A patent/MX2011012270A/es active IP Right Grant
- 2010-05-17 PT PT121597405T patent/PT2465523E/pt unknown
- 2010-05-17 MY MYPI2011005515A patent/MY168207A/en unknown
- 2010-05-17 WO PCT/GB2010/000997 patent/WO2010133834A2/en active Application Filing
- 2010-05-17 NZ NZ596300A patent/NZ596300A/xx not_active IP Right Cessation
- 2010-05-17 EP EP12159740.5A patent/EP2465523B1/en active Active
- 2010-05-17 UA UAA201114970A patent/UA110921C2/uk unknown
- 2010-05-17 CN CN201080032337.0A patent/CN102458445B/zh not_active Expired - Fee Related
- 2010-05-17 CA CA2762020A patent/CA2762020C/en not_active Expired - Fee Related
- 2010-05-17 BR BRPI1012845A patent/BRPI1012845A2/pt not_active IP Right Cessation
- 2010-05-17 JP JP2012511336A patent/JP5784009B2/ja not_active Expired - Fee Related
- 2010-05-17 ES ES12159740.5T patent/ES2525448T3/es active Active
- 2010-05-17 RS RS20140660A patent/RS53671B1/en unknown
- 2010-05-17 US US13/320,201 patent/US8703705B2/en not_active Expired - Fee Related
- 2010-05-17 EP EP10721533A patent/EP2432494A2/en not_active Withdrawn
-
2011
- 2011-11-07 IL IL216199A patent/IL216199A/en not_active IP Right Cessation
- 2011-11-17 ZA ZA2011/08446A patent/ZA201108446B/en unknown
- 2011-11-17 CO CO11156774A patent/CO6460780A2/es active IP Right Grant
- 2011-11-17 CL CL2011002893A patent/CL2011002893A1/es unknown
- 2011-12-16 EC EC2011011540A patent/ECSP11011540A/es unknown
-
2012
- 2012-11-07 HK HK12111247.4A patent/HK1173358A1/zh not_active IP Right Cessation
-
2014
- 2014-12-06 HR HRP20141182AT patent/HRP20141182T1/hr unknown
- 2014-12-15 SM SM201400186T patent/SMT201400186B/xx unknown
- 2014-12-17 CY CY20141101057T patent/CY1115832T1/el unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060917A2 (en) * | 2000-12-01 | 2002-08-08 | Regents Of The University Of Minnesota | Method to treat hemophilia |
WO2002098454A2 (en) * | 2001-05-31 | 2002-12-12 | D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
CN101889024A (zh) * | 2007-12-04 | 2010-11-17 | 艾匹托普技术(布里斯托尔)有限公司 | Fviii肽和它们用于耐受化血友病患者的用途 |
WO2009095646A2 (en) * | 2008-01-28 | 2009-08-06 | Circassia Limited | Peptides from factor viii |
WO2009095646A3 (en) * | 2008-01-28 | 2010-03-11 | Circassia Limited | Peptides from factor viii |
Non-Patent Citations (1)
Title |
---|
TAKURO SUGIHARA ET AL.: "IDENTIFICATION OF PLASMA ANTIBODY EPITOPES AND GENE ABNORMALITIES IN JAPANESE HEMOPHILIA A PATIENTS WITH FACTOR VIII INHIBITOR", 《NAGOYA J. MED. SCI.》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104903347A (zh) * | 2012-11-12 | 2015-09-09 | 艾匹托普国际股份有限公司 | 肽 |
CN104903347B (zh) * | 2012-11-12 | 2020-02-21 | 艾匹托普国际股份有限公司 | 肽 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101889024B (zh) | Fviii肽和它们用于耐受化血友病患者的用途 | |
CN102458445B (zh) | Fviii衍生肽 | |
KR102165486B1 (ko) | 펩타이드 | |
US10087233B2 (en) | Coagulation factor VIII with reduced immunogenicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: UNIVERSITEIT HASSELT Free format text: FORMER OWNER: APITOPE TECHNOLOGY (BRISTOL) LTD. Effective date: 20130118 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20130118 Address after: Di Pentti Beck, Belgium Applicant after: Universiteit Hasselt Address before: Bristol Applicant before: Apitope Technology (Bristol) Limited |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1173358 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1173358 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140611 Termination date: 20190517 |
|
CF01 | Termination of patent right due to non-payment of annual fee |